Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases
Colorectal Liver Metastases
Conditions: official terms
Liver Neoplasms - Neoplasm Metastasis
Conditions: Keywords
Colorectal liver metastases (CRLM), Tumor ablation, Irreversible electroporation (IRE), Interventional oncology, NanoKnife, Colorectal liver metastasis, unresectable and not-thermally ablative due to location near vulnerable structures like vessels or bile ducts
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Irreversible electroporation (IRE)
Type: Procedure
Overall Status
Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeastasis.

The purpose of this study is to investigate the efficacy of percutaneous and open IRE in the treatment of patients with colorectal liver metastases (CRLM) that are unsuitable for resection or thermal ablation due to vicinity to vulnerable structures such as vessels and bile ducts. Other objectives are safety, feasibility (technical success) and imaging characteristics on follow-up (PET-)CT and PET-MRI and the value of these imaging modalities in dianosing local site recurrence (LSR) or residual disease (RD).

29 patients with histologically confirmed colorectal carcinoma who present with unresectable and not thermally ablative CRLM< 3.5cm suitable for IRE will undergo percutaneous or open irreversible electroporation of the tumor using CT and ultrasound guidance. All (serious) adverse events are registered. One day post-IRE MRI is performed to assess technical success. Follow-up will consist of frequent (PET-)CT and (PET-)MRI scanning to localize residual or recurrent disease. Overall technique effectiveness is determined 1 year after treatment.

The investigators hypothesize that IRE for central CRLM will lead to good tumor control without causing severe complications.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histological or cytological documentation of primary colorectal tumor;

- Previous induction chemotherapy due to unresectability; no intra- or extrahepatic disease progression under induction chemotherapy; OR

- Previous chemotherapy for other CRLM, now presenting with renewed CRLM unsuitable for resection or thermal ablation;

- Liver metastases F-18-FDG PET avid and visible on ceCT, size ≤ 3,5 cm and not eligible for resection or thermal ablation due to location close to a vessel or bile duct;

- Age more than 18 years;

- ASA classification 0 - 3;

- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to definite inclusion:

- Hemoglobin ≥ 5.6 mmol/L;

- Absolute neutrophil count (ANC) ≥ 1,500/mm3;

- Platelet count ≥ 100*109/l;

- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);

- ALT and AST ≤ 2.5 x ULN

- Serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance > 50 ml/min;

- Prothrombin time or INR < 1.5 x ULN;

- Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed if this treatment can be interrupted as judged by the treating physician)

- Written informed consent

Exclusion Criteria:

- Lesion > 3,5 cm size;

- History of epilepsy;

- Extrahepatic metastases rendering local therapy unfeasible;

- History of cardiac disease:

- Congestive heart failure >NYHA class 2;

- Active Coronary Artery Disease (defined as myocardial infarction within 6 months prior to screening);

- Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers are permitted);

- Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen;

- Compromised liver function (e.g. signs of portal hypertension, INR > 1,5 without use of anticoagulants, ascites);

- Pregnant or breast-feeding subjects;

- Immunotherapy ≤ 6 weeks prior to the procedure;

- Chemotherapy ≤ 6 weeks prior to the procedure;

- Concomitant use of anti-convulsives and anti-arrhythmic drugs other than beta blockers for antiepileptic or antiarrhythmic purpose;

- Allergy to contrast media;

- Any implanted stimulation device;

- Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study
Academic Medical Center
Amsterdam, Noord-Holland, Netherlands
Status: Recruiting
Contact: Jantien A Vogel, MD - +31205669111 - j.a.vogel@amc.uva.nl
VU University Medical Center
Amsterdam, Noord-Holland, Netherlands
Status: Recruiting
Contact: Hester J Scheffer, MD - +31204444533 - scheffer.hester@gmail.com
Leiden University Medical Center
Leiden, Zuid-Holland, Netherlands
Status: Recruiting
Contact: Arian R van Erkel, MD, PhD - +3171 526 9111 - a.r.van_erkel@lumc.nl
Start Date
May 2014
Completion Date
May 2017
VU University Medical Center
VU University Medical Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page